Translational Development Acquisition (TDAC) Liabilities and Shareholders Equity (2023 - 2026)

Translational Development Acquisition's Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $183.3 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 3.82% year-over-year to $183.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $723.2 million (changed N/A YoY) and the FY2025 annual result came in at $181.7 million, up 3.83% from the prior year.
• Liabilities and Shareholders Equity was $183.3 million for Q1 2026 at Translational Development Acquisition, up from $181.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $183.3 million in Q1 2026 and bottomed at $2021.0 in Q4 2023.
• A 4-year average of $153.5 million and a median of $178.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 8659008.31% — and 2026, when it gained 3.82%.
• Translational Development Acquisition's Liabilities and Shareholders Equity stood at $2021.0 in 2023, then surged by 8659008.31% to $175.0 million in 2024, then advanced by 3.83% to $181.7 million in 2025, then advanced by 0.91% to $183.3 million in 2026.
• Business Quant data shows TDAC's Liabilities and Shareholders Equity at $183.3 million in Q1 2026, $181.7 million in Q4 2025, and $180.0 million in Q3 2025.